Toleranzia AB Logo

Toleranzia AB

TOL | ST

Overview

Corporate Details

ISIN(s):
SE0007438577 (+1 more)
LEI:
529900ARVN1D3A4CHI81
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Toleranzia AB is a biotechnology company developing therapies that utilize the immune system to treat rare autoimmune (orphan) diseases. The company's approach focuses on targeting the underlying cause of a disease, aiming to create curative or long-acting treatments that go beyond symptom management. Its lead drug candidate, TOL2, is in development for the treatment of the neuromuscular disease myasthenia gravis (MG). Toleranzia's pipeline also includes TOL3, a candidate for the treatment of the autoimmune blood vessel disease ANCA-vasculitis.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Toleranzia AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Toleranzia AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Toleranzia AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-04 Thomas Eldered Other Sell 12,000,000 5,100,000.00 SEK
2025-04-03 Thomas Eldered Other Sell 23,764,705 10,099,999.62 SEK

Peer Companies

Company Country Ticker View
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom OBD
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A biopharma firm that developed cannabinoid pain therapies, now in administration and ceased trading.
United Kingdom OCTHF
Oxurion NV Logo
Biopharmaceutical company providing Contract Research Organization (CRO) services to life sciences.
Belgium OXUR
PCI Biotech Holding Logo
Develops light-activated drug delivery for cancer, dermatology, and gene therapy manufacturing.
Norway PCIB
Pentixapharm Holding AG Logo
Develops first-in-class radiopharmaceuticals for cancer diagnosis and therapy (theranostics).
Germany PTP
PharmaLundensis AB Logo
Develops drugs to bind and excrete heavy metals for treating COPD, bronchitis, and depression.
Sweden PHAL
Pharnext Logo France ALPHA
Pherecydes Pharma Logo
Developing precision phage therapies for antibiotic-resistant bacterial infections.
France ALPHE
Philogen Logo
Develops antibody-based biopharmaceuticals for targeted cancer and inflammation treatment.
Italy PHIL
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC